業績

論文

  • Kamide D, Yamashita T, Araki K, Tomifuji M, Tanaka Y, Tanaka S, Shiozawa S, Shiotani A.
    Selective Activator Protein-1 Inhibitor T-5224 Prevents Lymph Node Metastasis in an Oral Cancer Model.
    Cancer Sci in press, 2016.
  • Shiozawa K, Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S , Shiozawa S.
    MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
    Arthritis Res Ther 18:55, 2016.
  • Ishida M, Ueki M, Morishita J, Ueno M, Shiozawa S, Maekawa N.
    T-5224, a selective inhibitor of c-Fos/activator protein-1, improves survival by inhibiting serum high mobility group box-1 in lethal lipopolysaccharide-induced acute kidney injury model.
    J Intensive Care 3:49, 2015.
  • Yoshida T, Yamashita K, Watanabe M, Koshizuka Y, Kuraya D, Ogura M, Asahi Y, Ono H, Emoto S, Mizukami T, Kobayashi N, Shibasaki S, Tomaru U, Kamachi H, Matsushita M, Shiozawa S, Hirono S, Todo S.
    The impact of c-Fos/Activator protein-1 inhibition on allogeneic pancreatic islet transplantation.
    Am J Transpl 15:2565-2575, 2015.
  • Verheul MK, Shiozawa K, Levarht EW, Huizinga TW, Toes RE, Trouw LA, Shiozawa S.
    Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent.
    Rheumatology 54:1930-1932, 2015.
  • Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M, REAL Study Group, Shiozawa S.
    Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
    Arthritis Res Ther 17:74, 2015.
  • Tanaka M, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M, REAL Study Group, Shiozawa S.
    The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) data base.
    Rheumatol Int 34:1729-36, 2014.
  • Cho SK, Sakai R, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Tanaka Y, Nakajima A, Yasuda S, Ihata A, Ezawa K, Won S, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Miyasaka N, Bae SC, Harigai M, REAL Study Group, Shiozawa S.
    A comparison of incidence and risk for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
    Mod Rheumatol 24:572-579, 2014.
  • Tsumiyama K, Shiozawa S.
    Induction of de novo autoimmune disease in normal mice upon repeated immunization with antigen.
    Methods Mol Biol 1142:85-90, 2014.
  • Shiozawa S, Uto K.
    Studies on the T cell receptor (TCR) revision of autoantibody-inducing CD4 T (aiCD4 T) cell.
    Methods Mol Biol 1142:65-73, 2014.
  • Miyazaki Y, Shiozawa S.
    In vivo cell transfer assay to detect autoreactive T cell subsets.
    Methods Mol Biol 1142:49-53, 2014.
  • Tsumiyama K, Hashiramoto A, Takimoto M, Tsuji-Kawahara, Miyazawa M,
    Shiozawa S.
    IFNγ-producing effector CD8 T lymphocytes cause immune glomerular injury by recognizing antigen presented as immune complex on target tissue.
    J Immunol 191:91-96, 2013.
  • Miyazaki Y, Tsumiyama K, Yamane T, Ito M, Shiozawa S.
    Expansion of PD-1-positive effector CD4 T cells in an experimental model of SLE: contribution to the self-organized criticality theory.
    Kobe J Med Sci 59:E64-E71, 2013.
  • Miyazaki Y, Tsumiyama K, Yamane T, Ito M, Shiozawa S .
    Self-organized criticality theory and the expansion of PD-1 positive effector CD4 T cells: search for autoantibody-inducing CD4 T cells.
    Front Immunol 4:87, 2013.
  • Yoshida K, Hashiramoto A, Okano T, Yamane T, Shibanuma N, Shiozawa S.
    TNF-α modulates expression of the circadian clock gene Per2 in rheumatoid synovial cells. 2013;42(4):276-80
    Scand J Rheumatol 42:276-280, 2013.
  • Kawasaki Y, Hashiramoto A, Okano T, Sakai Y, Yamane T, Shiozawa K, Shiozawa S,
    Hashiramoto A.
    Shorter disease duration in important for tocilizumab to achieve Boolean remission.
    Mod Rheumatol 23:1192-1197, 2013.
  • Yamada K, Ohno T, Aoki H, Semi K, Watanabe A, Moritake H, Shiozawa S,
    Kunisada T, Kobayashi Y, Toguchida J, Shimizu K, Hara A, Yamada Y.
    EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice.
    J Clin Invest 123:600-610, 2013.
  • Yoshida K, Inoue H, Komai K, Yamane T, Hashiramoto A, Shiozawa K, Shiozawa S.
    Mixed connective tissue disease (MCTD) is distinct from SLE: study of MICA and HLA gene polymorphism.
    Tissue Antigens 81:44-45, 2013.
  • Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T.
    A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study.
    Ann Rheum Dis 72:310-312, 2013.
  • Izuta S, Ueki M, Ueno M, Nishina K, Shiozawa S, Maekawa N.
    T-5224, a selective inhibitor of c-Fos/ activator protein-1, attenuates lipopolysaccharide-induced liver injury in mice.
    Biotechnol Lett 34:2175-2182, 2012.
  • Miyazaki H, Morishita J, Ueki K, Nishina K, Shiozawa S, Maekawa N.
    The effects of a selective inhibitor of c-Fos/activator protein-1 on endotoxin-induced acute kidney injury in mice.
    BMC Nephrology 13:153, 2012.
  • Tanaka C, Shiozawa K, Hashiramoto A, Shiozawa S.
    A study on the selection of DMARDs for combination therapy with adalimumab.
    Kobe J Med Sci 58:E41-E50, 2012.
  • Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Hashiramoto A, Nagawasa K, Miyasaka N, Harigai M, REAL Study Group, Shiozawa S.
    Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
    Arthritis Care Res 64:1125-1134, 2012.
  • Shiozawa K, Kawasaki Y, Yamane T, Yoshihara R, Tanaka Y, Uto K, Shiozawa S.
    Anticitrullinated protein antibody, but not its titer, is a predictor of radiographic progression and disease activity in rheumatoid arthritis.
    J Rheumatol 39:694-700, 2012.
  • Avouac J, Palumbo K, Zerr P, Tomcik M, Dees C, Horn A, Maurere B,
    Akhmetschina A, Beyer C, Schneider H, Shiozawa S, Distler O, Distler J.
    Inhibition of AP-1 signaling abrogates TGF-α mediated activation of fibroblasts and prevents experimental fibrosis.
    Arthritis Rheum 64:1642-1652, 2012.

総説

  • 塩沢俊一、腸内細菌叢が抗体治療の効果に影響を及ぼす
    臨床リウマチ 27:233, 2015.
  • 塩沢俊一、自己免疫疾患の発症病因
    臨床免疫・アレルギー科 64:169-179, 2015.
  • 塩沢俊一、乾癬性関節炎の遺伝素因
    臨床リウマチ 27:77-78, 2015.
  • 塩沢俊一、SLEの罹患率と有病率
    臨床リウマチ 27:1, 2015.
  • 塩沢俊一、関節リウマチの発症病因となる自己抗原リボゾーム蛋白RPL23Aの発見
    臨床リウマチ 26:239-240, 2014.
  • 塩沢俊一、抗CCP抗体と関節リウマチの発症病因
    臨床リウマチ 26:145-146, 2014.
  • 塩沢俊一、生物学的製剤時代にMTX単独療法はどの程度有効か
    臨床リウマチ 26:73-74, 2014.
  • 塩沢俊一、強皮症の成因TGFβ説のその後
    臨床リウマチ 26:1-3, 2014.
  • 塩沢俊一、全身性エリテマトーデスSLEの発症病因:自己臨界点説Self-organized criticality theory of autoimmunity
    臨床リウマチ 25:286-291, 2013.
  • 塩沢俊一、強直性脊椎炎の遺伝素因
    臨床リウマチ 25:231-233, 2013.
  • 塩沢俊一、Lupus psychosis
    心身医学 53:1095-1103, 2013.
  • 塩沢俊一、脳におけるグルココルチコイドの作用
    臨床リウマチ 25:143-145, 2013.
  • 塩沢俊一、強皮症の成因に関係するIL-13産生性CD8 T細胞
    臨床リウマチ 25:79-80, 2013.
  • 塩沢俊一、2010 ACR/EULAR 診断基準のパーフォーマンス
    臨床リウマチ 25:1-3, 2013.
  • 塩沢俊一、全身性エリテマトーデスの発症病因:自己臨界点説 self-organized criticality theory
    別府市医師会報 44:37-43, 2012.
  • 塩沢俊一、RAの関節・ADLの予後は最初の1年間の関節破壊で決まる
    臨床リウマチ 24:237-238, 2012.
  • 塩沢俊一、全身性血管炎に対するエタネルセプト治療:発癌率を増大?
    臨床リウマチ 24:161-62, 2012.
  • Shiozawa S. Pathogenesis of SLE and aiCD4 T cell: new insight on autoimmunity.
    Joint Bone Spine 79:428-430, 2012.
  • 塩沢俊一、CRPの正常化は炎症性脊椎疾患の仙腸関節炎の伸展が阻止されたことを示す
    臨床リウマチ 24:91-92, 2012.
  • 塩沢俊一、膠原病の原因としての感染症
    臨床リウマチ 24:1-2, 2012.
  • 塩沢俊一、全身性エリテマトーデス SLEの病因:自己臨界点説
    山口県医学雑誌 46:10-20, 2012.

著書

  • 塩沢俊一、「膠原病学」、改訂第6版、丸善、pp688、2015.7.
  • 塩沢俊一、関節リウマチの発症病因:自己免疫疾患の発症病因によせて、七川歓次監修、塩沢俊一他編
    「リウマチ病セミナーXXV」、pp21-29、永井書店、2014.12.
  • Shiozawa S, eds. Methods in Molecular Biology, vol. 1142: Arthritis Research, 2nd ed. pp1-204, Humana Press, New York, 2014.
  • 塩沢俊一、TCR: pMHC結合の構造とリウマチ性疾患の発症病因、七川歓次監修、塩沢俊一他編
    「リウマチ病セミナーXXIV」、pp99-112、永井書店、2013.12.
  • 塩沢俊一、関節リウマチ、笠倉正典他編、「器官病理学」、改訂14版、pp906-913、南山堂、2013.8.
  • 塩沢俊一、全身性エリテマトーデス、笠倉正典他編、「器官病理学」、改訂14版、pp900-906、南山堂、2013.8.
  • 塩沢俊一、混合性結合組織病、笠倉正典他編、「器官病理学」、改訂14版、pp897-900、
    南山堂、2013.8.
  • 塩沢俊一、「膠原病学」、改訂第5版、丸善、pp660、2012.
  • 塩沢俊一、全身性エリテマトーデスの発症病因—自己臨界点説、七川歓次監修塩沢俊一他編
    「リウマチ病セミナー XXIII」、pp10-18、永井書店、 2012.12.

国際学会、特別講演

  • 塩沢俊一、SLEの発症病因「自己臨界点説」および私の医師の心得
    渋川地区医師会学術講演会、渋川市、H28.1.18.
  • 塩沢俊一、自己免疫疾患の発症病因
    第2回JCRベーシックリサーチカンファレンス・特別講演、東京都、H27.10.3.
  • 塩沢俊一、SLEなど、膠原病の発症病因
    三緑会学術講演会・特別講演、神戸市、H27.7.4.
  • 塩沢俊一、全身性エリテマトーデスSLEの発症病因「自己臨界点説」の証明:SLEを誘導するaiCD4 T細胞の単離・同定
    第1回骨免疫学会 日本炎症・再生医学会共催セミナー、宮古島市、H27.7.2.
  • Tsumiyama K, Shiozawa S.
    Increase of endosomal Sec61 enhances antigen cross-presentation and induces immune glomerular injury: a novel ‘self-organized criticality theory’ explaining the cause of systemic lupus erythematosus.
    The 102nd Annual Meeting, American Association of Immunologist, May 8-12, 2015, New Orleans, USA.
  • Shiozawa S, Miyazaki Y, Tsumiyama K.
    Specifying the autoantibody-inducing CD4 T cell causing systemic lupus erythematosus out of PD-1+CD45RBlo122lo CD4 subpopulation using mass spectrometry.
    The 102nd Annual Meeting, American Association of Immunologist, May 8-12, 2015, New Orleans, USA.
  • 塩沢俊一、膠原病リウマチ性疾患の発症病因について
    第1回病因研究会別府シンポジウム・基調講演、別府市、H27.1.31.
  • 塩沢俊一、サイトカインからみたリウマチ性疾患
    第26回中之島リウマチ病セミナー、大阪市、H26.12.20.
  • 塩沢俊一、私の医師の心得
    第29回日本臨床リウマチ学会・教育講演、福岡市、H26.11.29.
  • 塩沢俊一、SLEおよび膠原病の発症病因
    第49回山口県リウマチ膠原病研究会・特別講演、宇部市、H26.11.26.
  • 塩沢俊一、自己臨界点説 —SLEの新しい病因仮説—
    第22回翠嶂会・特別講演、高山市、H26.11.23.
  • 積山賢塩沢俊一、「自己臨界点説」による膠原病の発症病因の解明
    第5回自己免疫疾患カンファレンス・特別講演、福岡市、H26.10.23.
  • Shiozawa K, Yamane T, Murata M, Tanaka C, Yo N, Yoshihara R, Tanaka Y, Tsumiyama K, Shiozawa S.
    Good response to methotrexate (MTX) and/or MTX plus adalimumab (ADA): 3yrs study results in patients with rheumatoid arthritis (RA).
    The 78th Annual Meeting, The American College of Rheumatology, November 15-19, 2014, Boston, USA.
  • Shiozawa K, Yamane T, Murata M, Tanaka C, Yo N, Yoshihara R, Tanaka Y, Tsumiyama K, Shiozawa S.
    Serum MMP-3 predicts a subgroup with no radiographic progression in rheumatoid arthritis patients with low-dose Methotrexate (MTX) monotherapy.
    The 78th Annual Meeting, The American College of Rheumatology, November 15-19, 2014, Boston, USA.
  • Shiozawa S. Self-organized criticality theory of autoimmunity explaining the cause of SLE.
    Special lecture, Claude Bernarde University Lyon, June 5, 2014, Lyon, France.
  • Shiozawa K, Yamane T, Murata M, Tanaka C, Yo N, Yoshihara R, Tanaka Y, Tsumiyama K, Shiozawa S.
    MMP3 predicts a subgroup of rheumatoid patients with structural remission under low-dose methotrexate (MTX) monotherapy.
    The 15th Annual Meeting, European League Against Rheumatism, June 11-14, 2014, Paris, France.
  • Tsumiyama K, Shiozawa S.
    Sec61 plays an essential role in facilitating antigen cross-presentation to induce immune glomerular injury: a novel ‘self-organized criticality theory’ explaining cause of SLE.
    The 101st Annual Meeting, American Association of Immunologist, May 2-6, 2014, Pittsburgh, USA.
  • Miyazaki Y, Tsumiyama K, Shiozawa S.
    The autoantibody-inducing CD4 T cell (aiCD4 T cell) causing to systemic lupus erythematosus (SLE) belongs to PD-1+CD45RBlo122lo CD4 subpopulation.
    The 101st Annual Meeting, American Association of Immunologist, May 2-6, 2014, Pittsburgh, USA.
  • 塩沢俊一、リウマチ性疾患の診療とそのトピックス
    Rheumatoid Arthritis Expert Meeting、秋田市、H26.3.20.
  • Shiozawa S. Self-organized criticality theory in the pathogenesis of SLE.
    Symposium on Human Papilloma Vaccines, February 25, 2014, Tokyo.
  • 塩沢俊一、抗CCP抗体とカルバミル化蛋白抗体
    第31回加古川・神戸大学連携リウマチカンファレンス講演、加古川市、H25.11.14.
  • Miyazaki Y, Tsumiyama K, Shiozawa S.
    PD-1+CD45RBlo122lo autoantibody-inducing CD4 T cells (aiCD4 T cells) as a key in the pathogenesis of systemic lupus erythematosus (SLE).
    The 77th Annual Meeting, The American College of Rheumatology, October 26-30, 2013, San Diego, USA.
  • Shiozawa S, Tanaka Y, Yoshihara R, Murata M, Yamane T, Tanaka C, Yo N, Shiozawa K.
    MMP3 as a predictor identifying a subgroup of rheumatoid patients who are successfully treated with Methotrexate (MTX) alone but still subject to radiographic progression.
    The 77th Annual Meeting, The American College of Rheumatology, October 26-30, 2013, San Diego, USA.
  • Shiozawa S, Trouw L, Shiozawa K.
    Anti-carbamylated protein antibody in Japanese patients with rheumatoid arthritis.
    The 77th Annual Meeting, The American College of Rheumatology, October 26-30, 2013, San Diego, USA.
  • 塩沢俊一、RAにおける抗CCP抗体の意義 ~病因と治療の視点から~
    第97回福岡リウマチ懇話会・教育講演、福岡市、2013.8.2.
  • Shiozawa S, Uto K, Tsumiyama K.
    Weak TCR signaling due to repeated immunization with antigen is the key for peripheral TCR revision generating aiCD4 T cell: implication to self-organized criticality theory.
    The 5th East Asia group of Rheumatology, May 31- June 1, 2013, Seoul, Korea.
  • Shiozawa S, Tsumiyama K, Miyazaki Y.
    Pathogenesis of systemic lupus erythematosus and aiCD4 T cell: new insight on autoimmunity.
    The 100th Annual Meeting, American Association of Immunologist, May 3-7, 2013, Honolulu, USA.
  • Shiozawa S, Uto K, Tsumiyama K.
    Weak TCR signaling due to repeated immunization with antigen is the key for peripheral TCR revision generating aiCD4 T cell: a novel self-organized criticality theory.
    The 100th Annual Meeting, American Association of Immunologist, May 3-7, 2013, Honolulu, USA.
  • Tsumiyama K, Shiozawa S.
    Antigen cross-presentation via Sec61 is indispensable for the development of lupus nephritis: a novel ‘self-organized criticality theory’ explaining the cause of SLE.
    The 100th Annual Meeting, American Association of Immunologist, May 3-7, 2013, Honolulu, USA.
  • Miyazaki Y, Tsumiyama K, Shiozawa S.
    The autoantibody-inducing CD4 T cell causing systemic lupus erythematosus belongs to CCR4+CD45RBlo122lo subpopulation.
    The 100th Annual Meeting, American Association of Immunologist, May 3-7, 2013, Honolulu, USA.
  • 塩沢俊一、リウマチ治療薬のコンセプト
    中津関節リウマチセミナー・特別講演、中津市、2013.4.5.
  • 塩沢俊一、膠原病の発症病因のトピックス:関連した新しい治療の方向性について
    第 21 回相模原リウマチ研究会・特別講演、相模原市、2013.1.29.
  • Shiozawa S, Miyazaki Y, Tsumiyama K.
    Interferon alpha and self-organized criticality theory.
    The 76th Annual Meeting, The American College of Rheumatology, November 9-14, 2012, Washington DC, USA.
  • Tsumiyama K, Shiozawa S.
    Sec61 is indispensable for antigen cross-presentation and the development of lupus nephritis: a novel ‘self-organized criticality theory’ explain the cause of systemic lupus erythematosus (SLE).
    The 76th Annual Meeting, The American College of Rheumatology, November 9-14, 2012, Washington DC, USA.
  • Miyazaki Y, Tsumiyama K, Shiozawa S.
    The autoantibody-inducing CD4 T cell (aiCD4 T cell) belongs to CCR4+CD45RBlo122lo CD4 subpopulation: a novel ‘self-organized criticality theory’ explains the cause of systemic lupus erythematosus.
    The 76th Annual Meeting, The American College of Rheumatology, November 9-14, 2012, Washington DC, USA.
  • Yoshida K, Hashiramoto A, Okano T, Shibanuma N, Shiozawa S.
    TNF alpha modulates the expression of circadian clock gene per2 via D-box motif in the promoter region in rheumatoid synovial cells.
    The 76th Annual Meeting, The American College of Rheumatology, November 9-14, 2012, Washington DC, USA.
  • Date T, Aikawa Y, Yamamoto T, Narita H, Hirono S, Shiozawa S.
    Combined effects of a c-Fos/AP-1 inhibitor T-5224 and methotrexate on collagen-induced arthritis in mice.
    The 76th Annual Meeting, The American College of Rheumatology, November 9-14, 2012, Washington DC, USA.
  • 塩沢俊一、リウマチの睡眠障害
    リウマチ疾患と生活習慣病フォーラム、大分市、2012.10.15.
  • 塩沢俊一、RAの新薬c-Fos阻害剤の開発およびSLEの発症病因の解明:自己臨界点説について
    別府市医師会メディカルセミナー、別府市、2012.10.13.
  • Shiozawa S, Tsumiyama K, Miyazaki Y.
    Interferon alpha and self-organized criticality theory of autoimmunity.
    The 3rd Annual Meeting, European Congress of Immunology, September 5-8, 2012, Glasgow, UK.
  • 塩沢俊一、SLEの解明とRAの抗サイトカイン病としての治癒の可能性
    第350回MOC研究会・特別講演、福岡市、2012.9.3.
  • 塩沢俊一、リウマチ性疾患と心身医学
    第53回日本心身医学会総会学術講演会・教育講演、鹿児島市、2012.5.25-26.
  • Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T,Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T.
    Continuation/discontinuation of methotrexate and clinical response to etanercept determine the radiographic progression/ repair in patients with rheumatoid arthritis: a subanalysis of 52-week results from the JESMR Study.
    The 13th Annual Meeting, European League Against Rheumatism, June 6-9, 2012, Berlin, Germany.
  • Tsumiyama K, Shiozawa S.
    Sec61 is essential for antigen cross-presentation and the development of lupus nephritis.
    The 99th Annual Meeting, American Association of Immunologist, May 4-8, 2012, Boston, USA.
  • Miyazaki Y, Tsumiyama K, Shiozawa S.
    CD45RBlo122lo autoantibody-inducing CD4 T cell (aiCD4 T cell) causes systemic lupus erytematosus.
    The 99th Annual Meeting, American Association of Immunologist, May 4-8, 2012, Boston, USA.

外部資金獲得状況

  • 積山賢 平成28年度文部科学省科研費 若手研究(B) 16K21219 2,210,000円
  • 積山賢 平成26年度文部科学省科研費 若手研究(B) 26870421 1,300,000円
  • 塩沢俊一 平成25年度文部科学省科研費 基盤研究(C) 25515003 5,200,000円
  • 塩沢俊一 委任経理金 2012年4月-2013年3月 4,900,000円
  • 塩沢俊一 移管(神戸大学) 2012年4月 4,000,000円